The upregulation of IL-8 in response to EGFR inhibition has been previously observed in other systems; for example, head and neck cancer cells resistant to erlotinib showed enhanced IL-8 secretion in the context of EMT [49]. Here, CXCL8 is linked to head and neck cancer.